CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.
Polymyalgia rheumatica - Management
Basis for recommendation
- These recommendations are based on expert opinion in published guidelines [Michet and Matteson, 2008; Salvarani et al, 2008], and published guidelines that are based on draft guidance from the British Society for Rheumatology [Dasgupta et al, 2007].
- Specialists may consider the use of steroid-sparing treatments such as disease-modifying antirheumatic drugs for people who experience frequent relapses.
© NHS Institute for Innovation and Improvement